127 related articles for article (PubMed ID: 30111966)
1. Understanding the reasons for provincial discordance in cancer drug funding-a survey of policymakers.
Srikanthan A; Penner N; Chan KKW; Sabharwal M; Grill A
Curr Oncol; 2018 Aug; 25(4):257-261. PubMed ID: 30111966
[TBL] [Abstract][Full Text] [Related]
2. Impact of the pan-Canadian Oncology Drug Review on provincial concordance with respect to cancer drug funding decisions and time to funding.
Srikanthan A; Mai H; Penner N; Amir E; Laupacis A; Sabharwal M; Chan KKW
Curr Oncol; 2017 Oct; 24(5):295-301. PubMed ID: 29089796
[TBL] [Abstract][Full Text] [Related]
3. Determinants of the Cancer Drug Funding Process in Canada.
Gotfrit J; Jackson A; Shin JJW; Stewart DJ; Mallick R; Wheatley-Price P
Curr Oncol; 2022 Mar; 29(3):1997-2007. PubMed ID: 35323362
[TBL] [Abstract][Full Text] [Related]
4. Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study.
Lexchin J
BMJ Open; 2019 Jul; 9(7):e030750. PubMed ID: 31350254
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada.
Meyers DE; Jenei K; Chisamore TM; Gyawali B
JAMA Intern Med; 2021 Apr; 181(4):499-508. PubMed ID: 33616606
[TBL] [Abstract][Full Text] [Related]
6. Challenges in striving to simultaneously achieve multiple resource allocation goals: the pan-Canadian Oncology Drug Review (pCODR) example.
McDonald H; Charles C; Elit L; Gafni A
J Mark Access Health Policy; 2016; 4():. PubMed ID: 27489586
[TBL] [Abstract][Full Text] [Related]
7. Conditional approval of cancer drugs in Canada: accountability and impact on public funding.
Andersen SK; Penner N; Chambers A; Trudeau ME; Chan KKW; Cheung MC
Curr Oncol; 2019 Feb; 26(1):e100-e105. PubMed ID: 30853815
[TBL] [Abstract][Full Text] [Related]
8. New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations.
Niraula S; Nugent Z
J Natl Compr Canc Netw; 2018 Dec; 16(12):1460-1466. PubMed ID: 30545993
[No Abstract] [Full Text] [Related]
9. Strategizing health technology assessment for containment of cancer drug costs in a universal health care system: Case of the pan-Canadian Oncology Drug Review.
Niraula S
Cancer; 2019 Sep; 125(18):3100-3103. PubMed ID: 31154671
[TBL] [Abstract][Full Text] [Related]
10. The prioritization preferences of pan-Canadian Oncology Drug Review members and the Canadian public: a stated-preferences comparison.
Skedgel C
Curr Oncol; 2016 Oct; 23(5):322-328. PubMed ID: 27803596
[TBL] [Abstract][Full Text] [Related]
11. Evolution of health technology assessment: best practices of the pan-Canadian Oncology Drug Review.
Rocchi A; Chabot I; Glennie J
Clinicoecon Outcomes Res; 2015; 7():287-98. PubMed ID: 26082654
[TBL] [Abstract][Full Text] [Related]
12. Examining the association between oncology drug clinical benefit and the time to public reimbursement.
Thomson S; Everest L; Witzke N; Jiao T; Delos Santos S; Nguyen V; Cheung MC; Chan KKW
Cancer Med; 2022 Jan; 11(2):380-391. PubMed ID: 34850587
[TBL] [Abstract][Full Text] [Related]
13. Health-related quality of life in oncology drug reimbursement submissions in Canada: A review of submissions to the pan-Canadian Oncology Drug Review.
Raymakers AJN; Regier DA; Peacock SJ
Cancer; 2020 Jan; 126(1):148-155. PubMed ID: 31544234
[TBL] [Abstract][Full Text] [Related]
14. Disparity in public funding of systemic therapy for metastatic renal cell carcinoma in Canada.
Jackson EB; Hotte SJ
Can Urol Assoc J; 2022 Nov; 16(11):E516-E522. PubMed ID: 35704937
[TBL] [Abstract][Full Text] [Related]
15. The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011-2017.
Skedgel C; Wranik D; Hu M
Pharmacoeconomics; 2018 Apr; 36(4):467-475. PubMed ID: 29353385
[TBL] [Abstract][Full Text] [Related]
16. Provincial elections and timing of cancer drug funding.
Srikanthan A; Gill SS; Chan KK
Curr Oncol; 2016 Jun; 23(3):154-63. PubMed ID: 27330343
[TBL] [Abstract][Full Text] [Related]
17. Characteristics of clinician input in Canadian funding decisions for cancer drugs: a cross-sectional study based on CADTH reimbursement recommendations.
Jenei K; Meyers DE
BMJ Open; 2023 Oct; 13(10):e066378. PubMed ID: 37844982
[TBL] [Abstract][Full Text] [Related]
18. Describing Sources of Uncertainty in Cancer Drug Formulary Priority Setting across Canada.
Jenei K; Peacock S; Burgess M; Mitton C
Curr Oncol; 2021 Jul; 28(4):2708-2719. PubMed ID: 34287280
[TBL] [Abstract][Full Text] [Related]
19. Methodological Issues in Economic Evaluations Submitted to the Pan-Canadian Oncology Drug Review (pCODR).
Masucci L; Beca J; Sabharwal M; Hoch JS
Pharmacoecon Open; 2017 Dec; 1(4):255-263. PubMed ID: 29441502
[TBL] [Abstract][Full Text] [Related]
20. Is there an economic rationale for cancer drugs to have a separate reimbursement review process for resource allocation purposes?
McDonald H; Charles C; Elit L; Gafni A
Pharmacoeconomics; 2015 Mar; 33(3):235-41. PubMed ID: 25424496
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]